April 23, 2020 / By ED SILVERMAN, ADAM FEUERSTEIN and MATTHEW HERPER The antiviral medicine remdesivir from Gilead Sciences failed to speed the improvement of patients with Covid-19 or prevent them from dying, according to results from a long-awaited clinical trial conducted in China. Gilead, however, said the data suggest a “potential benefit.” A summary of the study …